GlassScriptPhysician profile
Jeffery Davis Stone
NPI 1679592398
$2,726.97
in general payments reported to CMS, 2019-2025
30 companies · $709 in 2025
The $709 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $122 · 2021: $150 · 2022: $439 · 2023: $273 · 2024: $579 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $566.53 | 2022-2025 | Azstarys |
| Pfizer INC. | $223.96 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $219.38 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $191.29 | 2019-2024 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $174.28 | 2022-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $151.94 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $130.68 | 2022-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Welch Allyn | $117.60 | 2021 | |
| Sobi, INC | $117.06 | 2020-2023 | |
| Tris Pharma INC | $96.74 | 2019-2024 | Dyanavel Xr |
| Sanofi Pasteur INC. | $93.85 | 2019-2025 | |
| Glaxosmithkline, LLC. | $76.65 | 2019-2025 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $68.76 | 2019-2022 | |
| Verrica Pharmaceuticals INC. | $48.37 | 2024-2025 | Ycanth |
| Sanofi-Aventis U.S. LLC | $47.53 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $40.46 | 2019-2022 | |
| Shire North American Group INC | $39.82 | 2019 | |
| Alk-Abello, INC | $33.26 | 2025 | Neffy, Odactra, Grastek |
| Hologic Sales and Service, LLC | $32.40 | 2022-2024 | Aptima |
| Vertical Pharmaceuticals, LLC | $31.18 | 2019-2025 | Relexxii |
| Noven Therapeutics, LLC | $31.10 | 2024 | Xelstrym |
| Astrazeneca Pharmaceuticals LP | $29.55 | 2022-2023 | Flumist Quadrivalent |
| Genentech USA, INC. | $28.13 | 2019-2020 | |
| Adlon Therapeutics L.P. | $27.94 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $23.48 | 2024 | Daybue |
| Noven Pharmaceuticals, INC. | $20.36 | 2024 | Xelstrym |
| Organon LLC | $17.60 | 2025 | |
| Ironwood Pharmaceuticals, INC | $17.46 | 2024 | |
| Rhodes Pharmaceuticals L.P. | $17.07 | 2019 | |
| Abbvie INC. | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.